查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1676765

美沙拉嗪市場按產品形式、給藥途徑、用途、最終用戶和分銷管道分類 - 2025-2030 年全球預測

Mesalazine Market by Product Form, Route Of Administration, Application, End-User, Distribution Channel - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 181 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計美沙拉嗪市場價值在 2024 年將達到 17.6 億美元，在 2025 年達到 18.5 億美元，並以 5.15% 的複合年成長率成長，到 2030 年達到 23.8 億美元。

主要市場統計數據
基準年 2024 年 17.6億美元
預計 2025 年 18.5億美元
預測年份 2030 23.8億美元
複合年成長率（%） 5.15％

美沙拉嗪是治療各種發炎性腸道疾病腸道疾病的基石，它繼續重塑醫療保健領域的治療模式。本執行摘要對不斷發展的美沙拉嗪市場格局進行了深入分析，強調了關鍵成長領域、策略細分和新興競爭考察。由於配方的進步、治療通訊協定的轉變以及對以患者為中心的護理模式的更加關注，全球美沙拉嗪市場正在經歷重大轉變。藥物傳遞方法的創新和對發炎疾病的深入了解使美沙拉嗪成為各種臨床環境中的主要治療選擇。

近年來，臨床醫生和醫療保健決策者見證了我們對美沙拉嗪作用機制和治療結果的理解的快速進步。美沙拉嗪在緩解發炎性腸道疾病、克隆氏症和潰瘍性大腸炎等慢性疾病相關症狀方面發揮關鍵作用，凸顯了持續研究和實證臨床策略的重要性。產業相關人員越來越重視精準醫療方法，從而整合細分市場策略，根據特定患者的需求客製化產品配方。開發這些新興市場不僅可以改善臨床結果，還可以為市場擴張和競爭差異化帶來新的機會。

本報告詳細介紹了不斷變化的市場格局、透過多方面細分分析得出的競爭考察、區域概況、競爭情報以及針對行業領導者的可行建議。對於決策者、投資者和策略家來說，透徹了解這些動態對於將創新的、針對患者量身定做的解決方案帶到最前沿至關重要。本摘要提供了美沙拉嗪生態系統的全面觀點，使相關人員能夠應對當前複雜的製藥環境。

美沙拉嗪市場格局的變化：創新與策略發展

在過去幾年裡，美沙拉嗪市場經歷了變革性變化，重新定義了產業的策略方向。這些變化的核心是配方技術和給藥途徑的進步，顯著提高了患者的依從性和治療效果。先進的研究為新的藥物輸送系統鋪平了道路，從而提高了生物有效性並減少了副作用。差異化治療配方的出現使得針對特定患者群體和臨床情況制定個人化治療策略成為可能。

數位健康工具和遠端醫療的快速發展進一步推動了這種動態的市場環境，這有助於發炎疾病臨床管理的地理擴展和最佳化。增強的連接性和資料主導的決策使醫療保健提供者能夠準確評估治療結果並相應地調整給藥方案。這些進步已導致相關人員的關注點發生顯著轉變，從一刀切的做法轉向精準劑量和個人化治療。技術的採用不僅簡化了病患監測，而且還有助於識別潛在的安全問題並加快監管回應和合規調整。

此外，臨床實踐指南的改進和現實世界實踐中證據的不斷採用正在加速向更具適應性的以患者為中心的護理模式的轉變。研究機構、監管機構和製藥公司之間的合作努力正在幫助為安全性和有效性標準設定新的基準。這些變革的累積效應使美沙拉嗪成為必不可少的治療方法，開創了創新的新時代，並有望提高慢性發炎疾病患者的整體照護品質。

關鍵細分洞察詳細市場細分分析

詳細了解市場區隔就會發現美沙拉嗪市場的多面性。透過考慮產品劑型、給藥途徑、臨床應用、最終用戶偏好和分銷管道等變量，分析將更加豐富。例如，產品形態細分涉及對灌腸液、顆粒、直腸泡沫、栓劑、錠劑等各種形態的專門研究，每種形態在吸收率和患者依從性方面都具有獨特的優勢。同時，給藥途徑也很重要，因為要比較口服和直腸給藥途徑，以解釋便利性、劑量準確性和區域患者偏好的差異。

透過將市場分為克隆氏症、發炎性腸道疾病腸道疾病和潰瘍性大腸炎等疾病，應用細分提供了進一步的見解，每種疾病都有不同的臨床挑戰和治療複雜性。對於最終用戶，該報告透過將居家照護環境與醫院和診所進行對比，突出了治療環境的差異，不僅突出了患者管理的差異，還突出了不同醫療保健基礎設施的利用模式的差異。最後，透過研究醫院藥局、網路藥局和零售藥局的表現來詳細評估分銷管道，這些管道共同促進了美沙拉嗪產品的整體可用性和市場滲透率。

這種細分有助於詳細了解市場促進因素和障礙，使相關人員能夠根據病患小組和醫療保健提供者的特定需求調整其產品開發策略。綜合的見解指南投資決策和產品發布，這些決策和產品發布可以精準響應當地市場動態，確保治療解決方案保持創新和可及性。

目錄

第 1 章 簡介

第2章調查方法

第3章執行摘要

第4章 市場概況

第5章 市場洞察

  • 市場動態
    • 驅動程式
      • 全球發炎性腸道疾病和潰瘍性大腸炎發生率上升
      • 更重視個人化醫療和標靶治療
      • 加強胃腸道疾病治療政府經費投入與扶持政策
    • 限制因素
      • 製造和生產成本上升對價格造成越來越大的壓力
    • 機會
      • 藥物研發領域的策略合作與夥伴關係推動美沙拉嗪治療方法的創新
      • 創新臨床試驗設計探索新的美沙拉嗪配方
    • 任務
      • 區域市場監管合規要求嚴格且多樣
  • 市場區隔分析
    • 產品形式：顆粒因易於管理、劑量靈活而越來越受到青睞。
    • 應用：擴大美沙拉嗪在潰瘍性大腸炎的應用
  • 波特五力分析
  • PESTEL 分析
    • 政治的
    • 經濟
    • 社會
    • 技術的
    • 合法的
    • 環境

6. 美沙拉嗪市場依產品形式分類

  • 灌腸劑
  • 顆粒
  • 直腸形式
  • 栓劑
  • 藥片

7. 美沙拉嗪市場依給藥途徑分類

  • 口服
  • 直腸

8. 美沙拉嗪市場應用

  • 克隆氏症
  • 發炎性腸道疾病
  • 潰瘍性大腸炎

9. 美沙拉嗪市場（按最終用戶分類）

  • 家庭護理設置
  • 醫院和診所

第 10 章 美沙拉嗪市場依通路分類

  • 醫院藥房
  • 網路藥局
  • 零售藥局

第 11 章美洲美沙拉嗪市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

12. 亞太地區美沙拉嗪市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

13. 歐洲、中東和非洲的美沙拉嗪市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第14章 競爭格局

  • 2024 年市場佔有率分析
  • FPNV 定位矩陣，2024 年
  • 競爭情境分析
  • 戰略分析與建議

公司列表

  • AbbVie Inc.
  • Allergan Pharmaceuticals International, Ltd.
  • Amneal Pharmaceuticals, Inc.
  • Apotex Inc.
  • Axplora Group GmbH
  • Cambrex Corporation
  • Chemi SpA
  • CordenPharma International
  • Divi's Laboratories Limited
  • Dr. Falk Pharma GmbH
  • Ethypharm SAS
  • Ferring Pharmaceuticals
  • Fresenius Kabi
  • LGM Pharma
  • Lupin limited
  • Pfizer Inc.
  • Rosemont Pharmaceuticals Ltd.
  • Salix Pharmaceuticals, Inc.
  • Sun Pharmaceutical Industries Ltd.
  • Takeda Pharmaceutical Company Limited
  • Teva Pharmaceuticals
  • Tillotts Pharma Ltd.
  • Viatris Inc.
  • Zhejiang Hengkang Pharmaceutical Co. Ltd.
  • Zydus Pharmaceuticals, Inc.
Product Code: MRR-867BED9A9E9F

The Mesalazine Market was valued at USD 1.76 billion in 2024 and is projected to grow to USD 1.85 billion in 2025, with a CAGR of 5.15%, reaching USD 2.38 billion by 2030.

KEY MARKET STATISTICS
Base Year [2024] USD 1.76 billion
Estimated Year [2025] USD 1.85 billion
Forecast Year [2030] USD 2.38 billion
CAGR (%) 5.15%

Mesalazine, a cornerstone in the treatment of various inflammatory bowel conditions, continues to reshape therapeutic paradigms in the healthcare sector. This executive summary provides an in-depth analysis of the evolving market landscape for mesalazine, elucidating key areas of growth, strategic segmentation, and emerging competitive insights. The global mesalazine market has undergone significant transformations, driven by advances in pharmaceutical formulations, shifts in treatment protocols, and an increased focus on patient-centric care models. Innovation in drug delivery methods and a deeper understanding of inflammatory disorders have positioned mesalazine as a mainstay treatment option across various clinical settings.

In recent years, clinicians and healthcare decision-makers have witnessed rapid advancements in the understanding of underlying mechanisms of action and therapeutic outcomes related to mesalazine. Its pivotal role in mitigating symptoms associated with chronic conditions such as inflammatory bowel disease, Crohn's disease, and ulcerative colitis underscores the importance of ongoing research and evidence-based clinical strategies. Industry stakeholders are increasingly prioritizing precision medicine approaches, resulting in the integration of segmented market strategies that align product formulation with specific patient needs. These developments have not only facilitated improved clinical outcomes but also fostered novel opportunities for market expansion and competitive differentiation.

The ensuing sections delve deeper into transformative shifts within the market landscape, key insights derived from multifaceted segmentation analysis, regional distinctions, competitive intelligence, and actionable recommendations for industry leaders. It is essential for decision-makers, investors, and strategists to fully comprehend these dynamics to bring innovative, patient-tailored solutions to the forefront. This summary offers a comprehensive perspective on the mesalazine ecosystem, ensuring that stakeholders are well-equipped to navigate the complexities of the current pharmaceutical environment.

Transformative Shifts in the Mesalazine Market Landscape: Innovations and Strategic Developments

Over the past few years, the mesalazine market has experienced transformative shifts that have redefined the industry's strategic direction. Central to these transformations is the evolution in formulation technologies and administration routes, which have significantly enhanced patient adherence and treatment efficacy. Advanced research has paved the way for novel drug delivery systems, resulting in improved bioavailability and reduced adverse effects. The emergence of differentiated therapeutic formulations has allowed for personalized treatment strategies that cater to specific patient demographics and clinical scenarios.

This dynamic market environment is further propelled by the rapid evolution of digital health tools and telemedicine, which have contributed to geographical expansion and optimized clinical management of inflammatory conditions. Enhanced connectivity and data-driven decision-making have enabled healthcare providers to precisely evaluate treatment outcomes and tailor dosage regimens accordingly. These advancements have resulted in a noticeable shift in stakeholder focus-from a one-size-fits-all approach to precision dosing and individualized patient therapy. The incorporation of technology has not only streamlined patient monitoring but has also helped in the identification of potential safety concerns, expediting regulatory responses and compliance adjustments.

Additionally, refinements in clinical practice guidelines and the increasing adoption of real-world evidence are accelerating the transition toward more adaptive, patient-centered models of care. The collaborative efforts between research institutions, regulatory bodies, and pharmaceutical companies have been instrumental in setting new benchmarks for safety and efficacy standards. Collectively, these transformative shifts have positioned mesalazine as an essential therapeutic agent, ushering in a new era of innovation that promises to enhance the overall quality of care for patients afflicted with chronic inflammatory conditions.

Key Segmentation Insights: Detailed Analysis of Market Divisions

A detailed comprehension of market segmentation reveals the multifaceted nature of the mesalazine market. The analysis is enriched by considering variables across product formulation, routes of administration, application in clinical conditions, end-user preferences, and distribution channels. For instance, product form segmentation encompasses dedicated studies on various forms such as enema solutions, granules, rectal foams, suppositories, and tablets, each of which demonstrates unique advantages based on absorption rates and patient compliance. In parallel, the route of administration is critical as it compares the oral route with the rectal route, identifying disparities in convenience, dosage accuracy, and regional patient preferences.

The application-based segmentation offers further insights, categorizing the market by disease indications including Crohn's disease, inflammatory bowel disease, and ulcerative colitis, each presenting distinct clinical challenges and treatment complexities. Differentiating by end-user highlights the divergence in therapeutic settings, contrasting homecare environments with hospitals and clinics, thus underscoring not only patient management but also the variance in utilization patterns across diverse healthcare infrastructures. Finally, distribution channels are meticulously evaluated by studying the performance of hospital pharmacies, online pharmacies, and retail pharmacies, which collectively contribute to the overall accessibility and market penetration of mesalazine products.

Such segmentation facilitates a granular understanding of market drivers and barriers, enabling stakeholders to align product development strategies with the specific needs of distinct patient groups and healthcare providers. The integrated insights guide investment decisions and product launches that are finely tuned to regional market dynamics, ensuring that therapeutic solutions remain both innovative and accessible.

Based on Product Form, market is studied across Enemas, Granules, Rectal Foam, Suppositories, and Tablets.

Based on Route Of Administration, market is studied across Oral and Rectal.

Based on Application, market is studied across Crohn's Disease, Inflammatory Bowel Disease, and Ulcerative colitis.

Based on End-User, market is studied across Homecare Settings and Hospitals & Clinics.

Based on Distribution Channel, market is studied across Hospital Pharmacies, Online Pharmacies, and Retail Pharmacies.

Key Regional Insights: Geographical Trends and Market Dynamics

Regional analysis reveals distinct trends and opportunities that have a profound impact on the mesalazine market. The Americas continue to be at the forefront of advanced healthcare delivery systems and innovation, setting high benchmarks for clinical practices. Meanwhile, the Europe, Middle East & Africa region shows a balanced mix of mature healthcare setups and emerging economies, driving contributions through robust regulatory frameworks and increasing demand for affordable, effective therapies. The Asia-Pacific region, marked by rapid urbanization and improving healthcare infrastructure, is witnessing substantial growth driven by the expanding middle-class population, increased healthcare spending, and rising awareness about inflammatory conditions.

Understanding these regional variations is vital as each area reflects unique market drivers, regulatory policies, and cultural nuances that shape mesalazine adoption and distribution. Through continuous market monitoring and strategic regional customization, companies can tailor their outreach and product strategies to effectively serve these diverse populations.

Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

Key Companies Insights: Analyzing Market Leaders and Competitive Dynamics

The competitive landscape is characterized by a diverse group of established pharmaceutical companies and emerging players who are redefining market standards through innovation and strategic partnerships. Industry leaders such as AbbVie Inc., Allergan Pharmaceuticals International, Ltd., Amneal Pharmaceuticals, Inc., Apotex Inc., and Axplora Group GmbH have demonstrated robust market performance, complemented by contributions from Cambrex Corporation, Chemi S.p.A., and CordenPharma International. In parallel, companies such as Divi's Laboratories Limited, Dr. Falk Pharma GmbH, Ethypharm SAS, and Ferring Pharmaceuticals have been instrumental in driving technological innovations and clinical trial advancements.

Other significant contributors include Fresenius Kabi, LGM Pharma, Lupin Limited, Pfizer Inc., Rosemont Pharmaceuticals Ltd., Salix Pharmaceuticals, Inc., Sun Pharmaceutical Industries Ltd., and Takeda Pharmaceutical Company Limited. Adding further, Teva Pharmaceuticals, Tillotts Pharma Ltd., Viatris Inc., Zhejiang Hengkang Pharmaceutical Co. Ltd., and Zydus Pharmaceuticals, Inc. are recognized for their commitment to high safety standards and resilient supply chains. Collectively, these companies continue to influence the strategic direction of the mesalazine market, with proactive research and development investments solidifying their market positions as well as driving competitive differentiation through product excellence and customer-centric strategies.

The report delves into recent significant developments in the Mesalazine Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., Allergan Pharmaceuticals International, Ltd., Amneal Pharmaceuticals, Inc., Apotex Inc., Axplora Group GmbH, Cambrex Corporation, Chemi S.p.A., CordenPharma International, Divi's Laboratories Limited, Dr. Falk Pharma GmbH, Ethypharm SAS, Ferring Pharmaceuticals, Fresenius Kabi, LGM Pharma, Lupin limited, Pfizer Inc., Rosemont Pharmaceuticals Ltd., Salix Pharmaceuticals, Inc., Sun Pharmaceutical Industries Ltd., Takeda Pharmaceutical Company Limited, Teva Pharmaceuticals, Tillotts Pharma Ltd., Viatris Inc., Zhejiang Hengkang Pharmaceutical Co. Ltd., and Zydus Pharmaceuticals, Inc.. Actionable Recommendations for Industry Leaders: Strategic Moves for Market Leadership

For industry leaders looking to maintain or establish market prominence, the following recommendations provide strategic guidance based on in-depth analysis of current market conditions and future trends. First, companies must prioritize investment in research and development with a focus on the next generation of mesalazine formulations. By leveraging cutting-edge technology and robust clinical evidence, companies can enhance drug efficacy while minimizing adverse effects. Secondly, aligning product launches with regional market dynamics can result in a more effective penetration strategy; tailoring formulations to meet the cultural, economic, and regulatory specifics of various geographies is critical.

Moreover, forging strategic partnerships with key stakeholders in digital health and data analytics can bolster patient support programs and optimize treatment outcomes. Industry leaders should also consider diversifying distribution channels, balancing between traditional hospital pharmacies, innovative online platforms, and trusted retail outlets to ensure widespread accessibility. Finally, engaging in continuous post-market surveillance and real-world evidence studies will provide timely insights into drug performance and patient adherence, allowing for agile adaptations to clinical and market feedback. This proactive approach not only reinforces consumer trust but also positions companies at the forefront of industry innovation.

Conclusion: Strategic Insights and Future Directions in the Mesalazine Market

In conclusion, an expansive evaluation of the mesalazine market reveals an intricate tapestry of opportunities and challenges. The transformative shifts within product development, technology integration, and regional personalization have redefined treatment paradigms and created a dynamic environment ripe for innovation. Detailed segmentation across product forms, administration routes, applications, end-user environments, and distribution channels underscores the complexity of market dynamics and highlights key areas for subsequent focus.

The diverse regional landscape, spanning the Americas, Europe, Middle East & Africa, and Asia-Pacific, has further accentuated the need for tailored strategies that resonate with localized market conditions. Similarly, robust competitive dynamics driven by leading pharmaceutical companies set a high bar for safety, clinical efficacy, and patient-centric care. As the mesalazine market continues to evolve, a careful balance between technological innovation, strategic collaboration, and adaptive market approaches will be essential to sustaining growth and enhancing patient outcomes.

This comprehensive analysis stresses the importance of agility, continuous improvement, and forward-thinking strategies in an increasingly competitive global pharmaceutical market. It is incumbent upon industry stakeholders to adopt a holistic understanding of market trends and to harness these insights for sustained competitive differentiation and operational excellence.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rising incidence of inflammatory bowel diseases and ulcerative colitis globally
      • 5.1.1.2. Growing focus on personalized medicine and targeted therapies
      • 5.1.1.3. Increased government funding and supportive policies for the treatment of gastrointestinal disorders
    • 5.1.2. Restraints
      • 5.1.2.1. High manufacturing and production costs driving pricing pressures
    • 5.1.3. Opportunities
      • 5.1.3.1. Strategic collaborations and partnerships in pharmaceutical R&D fostering innovation in mesalazine therapies
      • 5.1.3.2. Innovative clinical trial designs to explore novel mesalazine formulations
    • 5.1.4. Challenges
      • 5.1.4.1. Strict and varying regulatory compliance requirements across different regional markets
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Product Form: Increasing preference for granules due to their ease of administration and flexible dosing
    • 5.2.2. Applications: Expanding application of mesalazine in ulcerative colitis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Mesalazine Market, by Product Form

  • 6.1. Introduction
  • 6.2. Enemas
  • 6.3. Granules
  • 6.4. Rectal Foam
  • 6.5. Suppositories
  • 6.6. Tablets

7. Mesalazine Market, by Route Of Administration

  • 7.1. Introduction
  • 7.2. Oral
  • 7.3. Rectal

8. Mesalazine Market, by Application

  • 8.1. Introduction
  • 8.2. Crohn's Disease
  • 8.3. Inflammatory Bowel Disease
  • 8.4. Ulcerative colitis

9. Mesalazine Market, by End-User

  • 9.1. Introduction
  • 9.2. Homecare Settings
  • 9.3. Hospitals & Clinics

10. Mesalazine Market, by Distribution Channel

  • 10.1. Introduction
  • 10.2. Hospital Pharmacies
  • 10.3. Online Pharmacies
  • 10.4. Retail Pharmacies

11. Americas Mesalazine Market

  • 11.1. Introduction
  • 11.2. Argentina
  • 11.3. Brazil
  • 11.4. Canada
  • 11.5. Mexico
  • 11.6. United States

12. Asia-Pacific Mesalazine Market

  • 12.1. Introduction
  • 12.2. Australia
  • 12.3. China
  • 12.4. India
  • 12.5. Indonesia
  • 12.6. Japan
  • 12.7. Malaysia
  • 12.8. Philippines
  • 12.9. Singapore
  • 12.10. South Korea
  • 12.11. Taiwan
  • 12.12. Thailand
  • 12.13. Vietnam

13. Europe, Middle East & Africa Mesalazine Market

  • 13.1. Introduction
  • 13.2. Denmark
  • 13.3. Egypt
  • 13.4. Finland
  • 13.5. France
  • 13.6. Germany
  • 13.7. Israel
  • 13.8. Italy
  • 13.9. Netherlands
  • 13.10. Nigeria
  • 13.11. Norway
  • 13.12. Poland
  • 13.13. Qatar
  • 13.14. Russia
  • 13.15. Saudi Arabia
  • 13.16. South Africa
  • 13.17. Spain
  • 13.18. Sweden
  • 13.19. Switzerland
  • 13.20. Turkey
  • 13.21. United Arab Emirates
  • 13.22. United Kingdom

14. Competitive Landscape

  • 14.1. Market Share Analysis, 2024
  • 14.2. FPNV Positioning Matrix, 2024
  • 14.3. Competitive Scenario Analysis
    • 14.3.1. Amneal strengthens its market footprint with the dual launch of mesalamine for inflammatory bowel disease
    • 14.3.2. Ethypharm expands its mesalazine portfolio in China
    • 14.3.3. Takeda's FDA approval of subcutaneous ENTYVIO signals a strategic transition from IV induction to patient-friendly
  • 14.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. AbbVie Inc.
  • 2. Allergan Pharmaceuticals International, Ltd.
  • 3. Amneal Pharmaceuticals, Inc.
  • 4. Apotex Inc.
  • 5. Axplora Group GmbH
  • 6. Cambrex Corporation
  • 7. Chemi S.p.A.
  • 8. CordenPharma International
  • 9. Divi's Laboratories Limited
  • 10. Dr. Falk Pharma GmbH
  • 11. Ethypharm SAS
  • 12. Ferring Pharmaceuticals
  • 13. Fresenius Kabi
  • 14. LGM Pharma
  • 15. Lupin limited
  • 16. Pfizer Inc.
  • 17. Rosemont Pharmaceuticals Ltd.
  • 18. Salix Pharmaceuticals, Inc.
  • 19. Sun Pharmaceutical Industries Ltd.
  • 20. Takeda Pharmaceutical Company Limited
  • 21. Teva Pharmaceuticals
  • 22. Tillotts Pharma Ltd.
  • 23. Viatris Inc.
  • 24. Zhejiang Hengkang Pharmaceutical Co. Ltd.
  • 25. Zydus Pharmaceuticals, Inc.

LIST OF FIGURES

  • FIGURE 1. MESALAZINE MARKET MULTI-CURRENCY
  • FIGURE 2. MESALAZINE MARKET MULTI-LANGUAGE
  • FIGURE 3. MESALAZINE MARKET RESEARCH PROCESS
  • FIGURE 4. MESALAZINE MARKET SIZE, 2024 VS 2030
  • FIGURE 5. GLOBAL MESALAZINE MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 6. GLOBAL MESALAZINE MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 7. GLOBAL MESALAZINE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL MESALAZINE MARKET SIZE, BY PRODUCT FORM, 2024 VS 2030 (%)
  • FIGURE 9. GLOBAL MESALAZINE MARKET SIZE, BY PRODUCT FORM, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL MESALAZINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2030 (%)
  • FIGURE 11. GLOBAL MESALAZINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL MESALAZINE MARKET SIZE, BY APPLICATION, 2024 VS 2030 (%)
  • FIGURE 13. GLOBAL MESALAZINE MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 14. GLOBAL MESALAZINE MARKET SIZE, BY END-USER, 2024 VS 2030 (%)
  • FIGURE 15. GLOBAL MESALAZINE MARKET SIZE, BY END-USER, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 16. GLOBAL MESALAZINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
  • FIGURE 17. GLOBAL MESALAZINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 18. AMERICAS MESALAZINE MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 19. AMERICAS MESALAZINE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 20. UNITED STATES MESALAZINE MARKET SIZE, BY STATE, 2024 VS 2030 (%)
  • FIGURE 21. UNITED STATES MESALAZINE MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 22. ASIA-PACIFIC MESALAZINE MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 23. ASIA-PACIFIC MESALAZINE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 24. EUROPE, MIDDLE EAST & AFRICA MESALAZINE MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 25. EUROPE, MIDDLE EAST & AFRICA MESALAZINE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 26. MESALAZINE MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 27. MESALAZINE MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. MESALAZINE MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL MESALAZINE MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL MESALAZINE MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL MESALAZINE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. MESALAZINE MARKET DYNAMICS
  • TABLE 7. GLOBAL MESALAZINE MARKET SIZE, BY PRODUCT FORM, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL MESALAZINE MARKET SIZE, BY ENEMAS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL MESALAZINE MARKET SIZE, BY GRANULES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL MESALAZINE MARKET SIZE, BY RECTAL FOAM, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL MESALAZINE MARKET SIZE, BY SUPPOSITORIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL MESALAZINE MARKET SIZE, BY TABLETS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL MESALAZINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL MESALAZINE MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL MESALAZINE MARKET SIZE, BY RECTAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL MESALAZINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL MESALAZINE MARKET SIZE, BY CROHN'S DISEASE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL MESALAZINE MARKET SIZE, BY INFLAMMATORY BOWEL DISEASE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL MESALAZINE MARKET SIZE, BY ULCERATIVE COLITIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL MESALAZINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL MESALAZINE MARKET SIZE, BY HOMECARE SETTINGS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL MESALAZINE MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL MESALAZINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL MESALAZINE MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL MESALAZINE MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL MESALAZINE MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 27. AMERICAS MESALAZINE MARKET SIZE, BY PRODUCT FORM, 2018-2030 (USD MILLION)
  • TABLE 28. AMERICAS MESALAZINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 29. AMERICAS MESALAZINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 30. AMERICAS MESALAZINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 31. AMERICAS MESALAZINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 32. AMERICAS MESALAZINE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 33. ARGENTINA MESALAZINE MARKET SIZE, BY PRODUCT FORM, 2018-2030 (USD MILLION)
  • TABLE 34. ARGENTINA MESALAZINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 35. ARGENTINA MESALAZINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 36. ARGENTINA MESALAZINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 37. ARGENTINA MESALAZINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 38. BRAZIL MESALAZINE MARKET SIZE, BY PRODUCT FORM, 2018-2030 (USD MILLION)
  • TABLE 39. BRAZIL MESALAZINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 40. BRAZIL MESALAZINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 41. BRAZIL MESALAZINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 42. BRAZIL MESALAZINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 43. CANADA MESALAZINE MARKET SIZE, BY PRODUCT FORM, 2018-2030 (USD MILLION)
  • TABLE 44. CANADA MESALAZINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 45. CANADA MESALAZINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 46. CANADA MESALAZINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 47. CANADA MESALAZINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 48. MEXICO MESALAZINE MARKET SIZE, BY PRODUCT FORM, 2018-2030 (USD MILLION)
  • TABLE 49. MEXICO MESALAZINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 50. MEXICO MESALAZINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 51. MEXICO MESALAZINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 52. MEXICO MESALAZINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 53. UNITED STATES MESALAZINE MARKET SIZE, BY PRODUCT FORM, 2018-2030 (USD MILLION)
  • TABLE 54. UNITED STATES MESALAZINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 55. UNITED STATES MESALAZINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 56. UNITED STATES MESALAZINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 57. UNITED STATES MESALAZINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 58. UNITED STATES MESALAZINE MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 59. ASIA-PACIFIC MESALAZINE MARKET SIZE, BY PRODUCT FORM, 2018-2030 (USD MILLION)
  • TABLE 60. ASIA-PACIFIC MESALAZINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 61. ASIA-PACIFIC MESALAZINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 62. ASIA-PACIFIC MESALAZINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 63. ASIA-PACIFIC MESALAZINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 64. ASIA-PACIFIC MESALAZINE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 65. AUSTRALIA MESALAZINE MARKET SIZE, BY PRODUCT FORM, 2018-2030 (USD MILLION)
  • TABLE 66. AUSTRALIA MESALAZINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 67. AUSTRALIA MESALAZINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 68. AUSTRALIA MESALAZINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 69. AUSTRALIA MESALAZINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 70. CHINA MESALAZINE MARKET SIZE, BY PRODUCT FORM, 2018-2030 (USD MILLION)
  • TABLE 71. CHINA MESALAZINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 72. CHINA MESALAZINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 73. CHINA MESALAZINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 74. CHINA MESALAZINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 75. INDIA MESALAZINE MARKET SIZE, BY PRODUCT FORM, 2018-2030 (USD MILLION)
  • TABLE 76. INDIA MESALAZINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 77. INDIA MESALAZINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 78. INDIA MESALAZINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 79. INDIA MESALAZINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 80. INDONESIA MESALAZINE MARKET SIZE, BY PRODUCT FORM, 2018-2030 (USD MILLION)
  • TABLE 81. INDONESIA MESALAZINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 82. INDONESIA MESALAZINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 83. INDONESIA MESALAZINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 84. INDONESIA MESALAZINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 85. JAPAN MESALAZINE MARKET SIZE, BY PRODUCT FORM, 2018-2030 (USD MILLION)
  • TABLE 86. JAPAN MESALAZINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 87. JAPAN MESALAZINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 88. JAPAN MESALAZINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 89. JAPAN MESALAZINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 90. MALAYSIA MESALAZINE MARKET SIZE, BY PRODUCT FORM, 2018-2030 (USD MILLION)
  • TABLE 91. MALAYSIA MESALAZINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 92. MALAYSIA MESALAZINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 93. MALAYSIA MESALAZINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 94. MALAYSIA MESALAZINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 95. PHILIPPINES MESALAZINE MARKET SIZE, BY PRODUCT FORM, 2018-2030 (USD MILLION)
  • TABLE 96. PHILIPPINES MESALAZINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 97. PHILIPPINES MESALAZINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 98. PHILIPPINES MESALAZINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 99. PHILIPPINES MESALAZINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 100. SINGAPORE MESALAZINE MARKET SIZE, BY PRODUCT FORM, 2018-2030 (USD MILLION)
  • TABLE 101. SINGAPORE MESALAZINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 102. SINGAPORE MESALAZINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 103. SINGAPORE MESALAZINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 104. SINGAPORE MESALAZINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 105. SOUTH KOREA MESALAZINE MARKET SIZE, BY PRODUCT FORM, 2018-2030 (USD MILLION)
  • TABLE 106. SOUTH KOREA MESALAZINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 107. SOUTH KOREA MESALAZINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 108. SOUTH KOREA MESALAZINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 109. SOUTH KOREA MESALAZINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 110. TAIWAN MESALAZINE MARKET SIZE, BY PRODUCT FORM, 2018-2030 (USD MILLION)
  • TABLE 111. TAIWAN MESALAZINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 112. TAIWAN MESALAZINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 113. TAIWAN MESALAZINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 114. TAIWAN MESALAZINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 115. THAILAND MESALAZINE MARKET SIZE, BY PRODUCT FORM, 2018-2030 (USD MILLION)
  • TABLE 116. THAILAND MESALAZINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 117. THAILAND MESALAZINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 118. THAILAND MESALAZINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 119. THAILAND MESALAZINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 120. VIETNAM MESALAZINE MARKET SIZE, BY PRODUCT FORM, 2018-2030 (USD MILLION)
  • TABLE 121. VIETNAM MESALAZINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 122. VIETNAM MESALAZINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 123. VIETNAM MESALAZINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 124. VIETNAM MESALAZINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 125. EUROPE, MIDDLE EAST & AFRICA MESALAZINE MARKET SIZE, BY PRODUCT FORM, 2018-2030 (USD MILLION)
  • TABLE 126. EUROPE, MIDDLE EAST & AFRICA MESALAZINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 127. EUROPE, MIDDLE EAST & AFRICA MESALAZINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 128. EUROPE, MIDDLE EAST & AFRICA MESALAZINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 129. EUROPE, MIDDLE EAST & AFRICA MESALAZINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 130. EUROPE, MIDDLE EAST & AFRICA MESALAZINE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 131. DENMARK MESALAZINE MARKET SIZE, BY PRODUCT FORM, 2018-2030 (USD MILLION)
  • TABLE 132. DENMARK MESALAZINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 133. DENMARK MESALAZINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 134. DENMARK MESALAZINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 135. DENMARK MESALAZINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 136. EGYPT MESALAZINE MARKET SIZE, BY PRODUCT FORM, 2018-2030 (USD MILLION)
  • TABLE 137. EGYPT MESALAZINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 138. EGYPT MESALAZINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 139. EGYPT MESALAZINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 140. EGYPT MESALAZINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 141. FINLAND MESALAZINE MARKET SIZE, BY PRODUCT FORM, 2018-2030 (USD MILLION)
  • TABLE 142. FINLAND MESALAZINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 143. FINLAND MESALAZINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 144. FINLAND MESALAZINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 145. FINLAND MESALAZINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 146. FRANCE MESALAZINE MARKET SIZE, BY PRODUCT FORM, 2018-2030 (USD MILLION)
  • TABLE 147. FRANCE MESALAZINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 148. FRANCE MESALAZINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 149. FRANCE MESALAZINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 150. FRANCE MESALAZINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 151. GERMANY MESALAZINE MARKET SIZE, BY PRODUCT FORM, 2018-2030 (USD MILLION)
  • TABLE 152. GERMANY MESALAZINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 153. GERMANY MESALAZINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 154. GERMANY MESALAZINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 155. GERMANY MESALAZINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 156. ISRAEL MESALAZINE MARKET SIZE, BY PRODUCT FORM, 2018-2030 (USD MILLION)
  • TABLE 157. ISRAEL MESALAZINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 158. ISRAEL MESALAZINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 159. ISRAEL MESALAZINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 160. ISRAEL MESALAZINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 161. ITALY MESALAZINE MARKET SIZE, BY PRODUCT FORM, 2018-2030 (USD MILLION)
  • TABLE 162. ITALY MESALAZINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 163. ITALY MESALAZINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 164. ITALY MESALAZINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 165. ITALY MESALAZINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 166. NETHERLANDS MESALAZINE MARKET SIZE, BY PRODUCT FORM, 2018-2030 (USD MILLION)
  • TABLE 167. NETHERLANDS MESALAZINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 168. NETHERLANDS MESALAZINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 169. NETHERLANDS MESALAZINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 170. NETHERLANDS MESALAZINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 171. NIGERIA MESALAZINE MARKET SIZE, BY PRODUCT FORM, 2018-2030 (USD MILLION)
  • TABLE 172. NIGERIA MESALAZINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 173. NIGERIA MESALAZINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 174. NIGERIA MESALAZINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 175. NIGERIA MESALAZINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 176. NORWAY MESALAZINE MARKET SIZE, BY PRODUCT FORM, 2018-2030 (USD MILLION)
  • TABLE 177. NORWAY MESALAZINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 178. NORWAY MESALAZINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 179. NORWAY MESALAZINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 180. NORWAY MESALAZINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 181. POLAND MESALAZINE MARKET SIZE, BY PRODUCT FORM, 2018-2030 (USD MILLION)
  • TABLE 182. POLAND MESALAZINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 183. POLAND MESALAZINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 184. POLAND MESALAZINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 185. POLAND MESALAZINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 186. QATAR MESALAZINE MARKET SIZE, BY PRODUCT FORM, 2018-2030 (USD MILLION)
  • TABLE 187. QATAR MESALAZINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 188. QATAR MESALAZINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 189. QATAR MESALAZINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 190. QATAR MESALAZINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 191. RUSSIA MESALAZINE MARKET SIZE, BY PRODUCT FORM, 2018-2030 (USD MILLION)
  • TABLE 192. RUSSIA MESALAZINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 193. RUSSIA MESALAZINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 194. RUSSIA MESALAZINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 195. RUSSIA MESALAZINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 196. SAUDI ARABIA MESALAZINE MARKET SIZE, BY PRODUCT FORM, 2018-2030 (USD MILLION)
  • TABLE 197. SAUDI ARABIA MESALAZINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 198. SAUDI ARABIA MESALAZINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 199. SAUDI ARABIA MESALAZINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 200. SAUDI ARABIA MESALAZINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 201. SOUTH AFRICA MESALAZINE MARKET SIZE, BY PRODUCT FORM, 2018-2030 (USD MILLION)
  • TABLE 202. SOUTH AFRICA MESALAZINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 203. SOUTH AFRICA MESALAZINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 204. SOUTH AFRICA MESALAZINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 205. SOUTH AFRICA MESALAZINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 206. SPAIN MESALAZINE MARKET SIZE, BY PRODUCT FORM, 2018-2030 (USD MILLION)
  • TABLE 207. SPAIN MESALAZINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 208. SPAIN MESALAZINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 209. SPAIN MESALAZINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 210. SPAIN MESALAZINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 211. SWEDEN MESALAZINE MARKET SIZE, BY PRODUCT FORM, 2018-2030 (USD MILLION)
  • TABLE 212. SWEDEN MESALAZINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 213. SWEDEN MESALAZINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 214. SWEDEN MESALAZINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 215. SWEDEN MESALAZINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 216. SWITZERLAND MESALAZINE MARKET SIZE, BY PRODUCT FORM, 2018-2030 (USD MILLION)
  • TABLE 217. SWITZERLAND MESALAZINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 218. SWITZERLAND MESALAZINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 219. SWITZERLAND MESALAZINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 220. SWITZERLAND MESALAZINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 221. TURKEY MESALAZINE MARKET SIZE, BY PRODUCT FORM, 2018-2030 (USD MILLION)
  • TABLE 222. TURKEY MESALAZINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 223. TURKEY MESALAZINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 224. TURKEY MESALAZINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 225. TURKEY MESALAZINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 226. UNITED ARAB EMIRATES MESALAZINE MARKET SIZE, BY PRODUCT FORM, 2018-2030 (USD MILLION)
  • TABLE 227. UNITED ARAB EMIRATES MESALAZINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 228. UNITED ARAB EMIRATES MESALAZINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 229. UNITED ARAB EMIRATES MESALAZINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 230. UNITED ARAB EMIRATES MESALAZINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 231. UNITED KINGDOM MESALAZINE MARKET SIZE, BY PRODUCT FORM, 2018-2030 (USD MILLION)
  • TABLE 232. UNITED KINGDOM MESALAZINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 233. UNITED KINGDOM MESALAZINE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 234. UNITED KINGDOM MESALAZINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 235. UNITED KINGDOM MESALAZINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 236. MESALAZINE MARKET SHARE, BY KEY PLAYER, 2024
  • TABLE 237. MESALAZINE MARKET, FPNV POSITIONING MATRIX, 2024